These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 907390

  • 1. Immune RNA therapy for renal cell carcinoma: survival and immunologic monitoring.
    Ramming KP, deKernion JB.
    Ann Surg; 1977 Oct; 186(4):459-67. PubMed ID: 907390
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Advanced renal cell carcinoma: treatment with xenogeneic immune ribonucleic acid and appropriate surgical resection.
    Skinner DG, Dekernion JB, Brower PA, Ramming KP, Pilch YH.
    J Urol; 1976 Mar; 115(3):246-50. PubMed ID: 943577
    [Abstract] [Full Text] [Related]

  • 4. In vivo effect and parallel in vitro lymphocyte-mediated tumor cytolysis after Phase I xenogeneic immune RNA treatment of patients with widespread melanoma or metastatic renal cell carcinoma.
    Steele G, Wang BS, Richie J, Wilson RE, Ervin T, Yankee R, Fallon M, Mannick JA.
    Cancer Res; 1980 Jul; 40(7):2377-82. PubMed ID: 6155992
    [No Abstract] [Full Text] [Related]

  • 5. In vivo and in vitro effects of xenogeneic immune ribonucleic acid in patients with advanced renal cell carcinoma: a phase I study.
    Richie JP, Wang BS, Steele GD, Wilson RE, Mannick JA.
    J Urol; 1981 Jul; 126(1):24-8. PubMed ID: 6166758
    [Abstract] [Full Text] [Related]

  • 6. Immune cytolysis of human renal carcinoma mediated by xenogeneic immune ribonucleic acid.
    Brower PA, Dekernion JB, Ramming KP.
    J Urol; 1976 Mar; 115(3):243-5. PubMed ID: 1255883
    [Abstract] [Full Text] [Related]

  • 7. Results of xenogeneic I-RNA therapy in patients with metastatic renal cell carcinoma.
    Steele G, Wang BS, Richie JP, Ervin T, Yankee R, Mannick JA.
    Cancer; 1981 Mar 15; 47(6):1286-8. PubMed ID: 6164471
    [Abstract] [Full Text] [Related]

  • 8. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A, Shvarts O, Figlin RA.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [Abstract] [Full Text] [Related]

  • 9. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.
    J Urol; 2001 Jul 15; 166(1):68-72. PubMed ID: 11435825
    [Abstract] [Full Text] [Related]

  • 10. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J, Kaplan A, Dorey F, Figlin R, Belldegrun A.
    J Urol; 1999 Jul 15; 162(1):46-50. PubMed ID: 10379737
    [Abstract] [Full Text] [Related]

  • 11. Current treatment of metastatic renal cell carcinoma with xenogeneic immune ribonucleic acid.
    Richie JP, Steele GD, Wilson RE, Ervin T, Wang BS, Mannick JA.
    J Urol; 1984 Feb 15; 131(2):236-8. PubMed ID: 6199519
    [Abstract] [Full Text] [Related]

  • 12. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK.
    Cancer Biother Radiopharm; 2001 Feb 15; 16(1):47-54. PubMed ID: 11279797
    [Abstract] [Full Text] [Related]

  • 13. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A.
    J Clin Oncol; 1999 Feb 15; 17(2):523-8. PubMed ID: 10080595
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy of renal cell carcinoma.
    deKernion JB.
    Prog Clin Biol Res; 1984 Feb 15; 153():409-21. PubMed ID: 6206509
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapy of disseminated renal cell carcinoma with transfer factor.
    Montie JE, Bukowski RM, Deodhar SH, Hewlett JS, Stewart BH, Straffon RA.
    J Urol; 1977 May 15; 117(5):553-6. PubMed ID: 859196
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy of cancer with "immune" RNA. A preliminary report.
    Pilch YH, de Kernion JB, Skinner DG, Ramming KP, Schick PM, Fritze D, Brower P, Kern DH.
    Am J Surg; 1976 Nov 15; 132(5):631-7. PubMed ID: 984310
    [Abstract] [Full Text] [Related]

  • 17. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A.
    Cancer; 2003 Dec 15; 98(12):2566-75. PubMed ID: 14669275
    [Abstract] [Full Text] [Related]

  • 18. The detection and clinical significance of antibodies to tumor-associated antigens in patients with renal cell carcinoma.
    Dekernion JB, Ramming KP, Gupta RK.
    J Urol; 1979 Sep 15; 122(3):300-5. PubMed ID: 469998
    [Abstract] [Full Text] [Related]

  • 19. Treatment of renal cell carcinoma with renal infarction, delayed nephrectomy, medroxyprogesterone, and xenogeneic immune RNA.
    Weigel JW, Mebust WK, Foret JD, Noble MJ, Votapka T, Krishnan EC, Jewell WR.
    Urology; 1985 Feb 15; 25(2):103-5. PubMed ID: 3969752
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
    Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Talamini R.
    Cancer; 1996 Jun 15; 77(12):2560-6. PubMed ID: 8640706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.